Discover Stoke Therapeutics' innovative RNA-based treatments like zorevunersen for Dravet syndrome, with a promising pipeline ...

Rare diseases have become an attractive target for pharmaceutical companies both in Australia and internationally with ...

Phil and Claire Drinkwater have raised more than £11,000 for charity since the loss of their 'joyful' son Jude ...

Company to host a webcasttoday at 8:30 a.m. Eastern TimeNEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the ...

In particular, its leading candidate is hands down TSHA-102 for Rett syndrome. The way this therapy works is by using “self-complementary” adeno viruses [scAAV] to deliver its treatment.

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmac ...

Anavex Life Sciences Corp. (NASDAQ: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, ...

The company's aggressive push into European markets with its Rett syndrome treatment, trofinetide, underscores its strategic focus on expanding globally. This move is bolstered by robust clinical ...

Jones Trading initiated coverage on ProQR Therapeutics N.V. (NASDAQ:PRQR) with a Buy rating and set a price target of $11.00, representing significant upside from the current price of $2.19. The ...